Summary
Urticaria may develop in response to a number of stimuli such as allergic reactions, drugs, cold, pressure, stings and, most interestingly, neuropsychological upheavals. Classical treatment has utilised H1-receptor antagonists, in view of the fact that histamine released from local mast cells acts on H1-receptors on the vasculature and participates in the pathophysiology of this syndrome. More recently, H2-receptor antagonists have also been tried, alone or in combination, with encouraging results. The question still remains why H2-receptor antagonists should have any beneficial effect since H2-receptors are mostly present on exocrine cells and on T-suppressor lymphocytes, where they are stimulatory, or mast cells, where they are auto-inhibitory. Possible explanations may include the ratio of H1- to H2-receptors on local vasculature and the effect of H2-antagonists on responses elicited through nervous system activity via cholinergic or neuropeptidergic neurons. Finally, evidence is presented that certain tricyclic H-receptor antagonists may have powerful inhibitory effects on secretion from both peripheral and central nervous system mast cells, as well as from neurons. The possible role of H3-receptors in this process is also discussed.
At present, the available evidence does not justify the routine use of H2-antagonists in the treatment of urticaria.
Similar content being viewed by others
References
Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302: 832–837, 1983
Avella J, Binder HJ, Madsen JE. Effect of histamine H2-receptor antagonists on delayed hypersensitivity. Lancet 1: 624–626, 1978
Baker DE, Filicetti M. Nizatidine: a new H2-antagonist. Practical Gastroenterology 12: 12–15, 1988
Barnes PJ. Airway neuropeptides and asthma. Trends in Pharmacological Sciences 6: 24–27, 1987
Bateman DN, Chapman PH, Rawlins MD. The effects of astemizole on histamine-induced weal and flare. European Journal of Clinical Pharmacology 25: 547–551, 1983
Beck HI, Cramers M, Herlin T, Søndergaard I, Zachariae H. Comparison of oxatomide and clemastine in the treatment of chronic urticaria: a double blind study. Dermatologica 171: 49–51, 1985
Berman BA, Ross RN, Sly RM. Urticaria. Cutis 30: 696, 700–701, 19–20, 1982
Bernstein IL, Bernstein DI. Efficacy and safety of aztemizole, a long-acting and nonsedating H1 antagonist for the treatment of chronic idiopathic urticaria. Journal of Allergy and Clinical Immunology 77: 37–42, 1986
Cainelli T, Seidenari S, Valsecchi R, Mosca M. Double-blind comparison of astemizole and terfenadine in the treatment of chronic urticaria. Pharmatherapeutica 4: 679–686, 1986
Cap JP, Schwanitz HJ, Czametzki BM. Effect of ketotifen in urticaria factitia and urticaria cholinergica in a cross-over double blind trial. Hautarzt (Berlin) 36: 509–511, 1985
Cerio R, Lessof NH. Treatment of chronic idiopathic urticaria with terfenadine. Clinical Allergy 14: 139–141, 1984
Chand N, Pillar J, Diamandis W, Perhach JL, Sofia RD. Inhibition of calcium ionophore (A23187)-stimulated histamine release from rat peritoneal mast cells by azelastine: implications for its mode of action. Pediatric Pharmacology 3: 287–292, 1983
Cochrane DE, Emigh C, Levine G, Carraway RE, Leeman SE. Neurotensin alters cutaneous vascular permeability and stimulates histamine release from isolated skin. Annals of the New York Academy of Sciences 400: 396–397, 1982
Connell JT. Pharmacology and clinical efficacy of terfenadine, a new H1-receptor antagonist. Pharmacology 5: 201–208, 1985
Cook J, Shuster S. The effect of H1 and H2 receptor antagonists on the dermographic response. Acta Dermato-Venereologica 63: 260–262, 1983a
Cook LJ, Shuster S. Lack of effect of cimetidine in chronic-idiopathic urticaria. Acta Dermato-Venereologica 63: 265–267, 1983b
Coutts A, Breaves MW. Evaluation of six antihistamines in vitro and in patients with urticaria. Clinical and Experimental Dermatology 7: 529–535, 1982
Curtis AC, Owens BB. Centennial paper: beta dimethylaminoethyl benzhydryl ether hydroxhloride (benadryl) in the treatment of urticaria. Archives of Dermatology 119: 438–441, 1983
Denney DL. Inhibition by cromolyn Na, promethazine and cyproheptadine of histamine release from peritoneal cells induced by antigen, 48/80 or A23187. Federation Proceedings 40: 1025, 1981
Diller G, Orfanos CE. Management of idiopathic urticaria with H1 and H2 antagonists: a cross-over double blind long-term study. Zeitschrift für Hautkrankheiten 58: 785–793, 1983
Dimitriadou V, Aubineau P, Taxi J, Seylaz J. Ultrastructural evidence for a functional unit between nerve fibers and type II cerebral mast cells in the cerebral vascular wall. Neuroscience 22: 621–630, 1987
Duc J, Pecoud A. Successful treatment of idiopathic cold urticaria with the association of H1 and H2 antagonists: a case report. Annals of Allergy 56: 355–357, 1986
Farnam J, Grant JA, Guernsey BG, Jorizzo JL, Petrusa ER. Successful treatment of chronic idiopathic urticaria and angioedema with cimetidine alone. Journal of Allergy and Clinical Immunology 73: 842–845, 1984
Farnam J, Grant JA, Lett-Brown MA, Russell WL, Henry DP. Combined cold- and heat-induced cholinergic urticaria. Journal of Allergy and Clinical Immunology 78: 353–357, 1986
Ferguson J, MacDonald KJ, Kenicer KJ. Terfenadine and placebo compared in the treatment of chronic idiopathic urticaria: a randomised double-blind study. British Journal of Clinical Pharmacology 20: 639–641, 1985
Fischer B, Schmutzler W. Inhibition by azelastine of the immunologically induced histamine release from isolated guinea pig mast cells. Arzneimittel-Forschung 31: 1193–1195, 1981
Foreman JC. Neuropeptides and the pathogenesis of allergy. Allergy 41: 1–11, 1987
Fox RW, Lockey RF, Bukantz SC, Serbousek D. The treatment of mild to severe chronic idiopathic urticaria with astemizole: double-blind and open trials. Journal of Allergy and Clinical Immunology 78: 1159–1166, 1986
Galli SJ, Dvorak AM, Dvorak H. Basophils and mast cells: insights into their biology, secretory patterns, and function. Progress in Allergy 34: 1–141, 1984
Goetzl ET, Chernov T, Renold F, Payan DG. Neuropeptide regulation of the expression of immediate hypersensitivity. Journal of Immunology 135: 802–805, 1985
Goldschmidt RC, Hough LB, Glick SD, Padawer J. Mast cells in rat thalamus: nuclear localization, sex difference and left-right asymmetry. Brain Research 323: 209–217, 1985
Goldsobel AB, Rohr AS, Siegel SC, Spector SL, Katz RM, et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. Journal of Allergy and Clinical Immunology 78: 867–873, 1986
Greene SL, Reed CE, Schroeter AL. Double-blind cross-over study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. Journal of American Academy of Dermatology 12: 669–675, 1985
Guschin IS, Kaminka ME, Deryugin IL. Inhibition of noncytotoxic histamine liberation from isolated mast cells by antihistamines in rats. Bulletin of Experimental Biology and Medicine (Russian) 86: 1367–1370, 1979
Harto A, Sendagorta E, Ledo A. Doxepin in the treatment of chronic urticaria. Dermatologica 170: 90–93, 1983
Harvey RP, Wegs J, Schocket AL. A controlled trial of therapy in chronic urticaria. Journal of Allergy and Clinical Immunology 68: 262–266, 1981
Heltianu C, Simionescu M, Simionescu N. Detection of histamine receptors at cellular level. Biochemical Pharmacology 33: 343–346, 1984
Hirschowitz RJ. H-2 histamine receptors. Annual Review of Pharmacology and Toxicology 19: 203–244, 1979
Houston DP, Bressler RB, Kaliner M, Sowell LK, Baylor MW. Prevention of mast-cell degranulation by ketotifen in patients with physical urticarias. Annals of Internal Medicine 104: 507–510, 1986
Ishikawa S, Sperelakis N. A novel class (H3) of histamine receptors of perivascular nerve terminals. Nature 327: 158–160, 1987
Kailasam V, Mathews KP. Controlled clinical assessment of astemizole in the treatment of chronic idiopathic urticaria and angioedema. Journal of the American Academy of Dermatology 16: 797–804, 1987
Kaliner M, Sigler R, Summers R, Shelhamer JH. Effects of infused histamine: analysis of the effects of H-1 histamine receptor antagonist on cardiovascular and pulmonary responses. Journal of Allergy and Clinical Immunology 68: 365–371, 1981
Kaplan AP. Chronic urticaria: possible causes, suggested treatment alternatives. Postgraduate Medicine 74: 209–215, 218–222, 1983
Kaplan AP. Exercise-induced hives. Journal of Allergy and Clinical Immunology 73: 704–707, 1984
Katayama I, Doi T, Nishioka K, Maeyama K, Yamatodani A. Acquired cold urticaria: H1 and H2 antagonists versus cold induced histamine release. Journal of Dermatology (Tokyo) 10: 377–382, 1983
Klemp P, Staberg B, Agdal N, Munkvad IM. Successful treatment of cold angio-oedema by H2-antihistamine therapy. Acta Dermato-Venereologica 63: 262–264, 1983
Konstantinidou AD, Lambracht-Hall M, Theoharides TC. Inhibition of brain mast cell secretion by tricyclic antidepressants. Neuropharmacology, in press, 1989
Krause LB, Shuster S. H1-receptor-active histamine not sole cause of chronic idiopathic urticaria. Lancet 2: 929–930, 1984a
Krause LB, Shuster S. The effect of terfenadine on dermographic wealing. British Journal of Dermatology 110: 73–79, 1984b
Krause LB, Shuster S. A comparison of astemizole and chlorpheniramine in dermographic urticaria. British Journal of Dermatology 112: 447–453, 1985
Kurz K. Treatment of urticaria with the new H1 antihistaminic astemizole with special reference to the time of onset of effect and maximum effect. Zeitschrift für Hautkrankheiten 61: 1646–1652, 1986
Lahti A, McDonald DM, Tammi R, Maibach HI. Pharmacological studies on nonimmunologic contact urticaria in guinea pigs. Archives of Dermatological Research 279: 44–49, 1986
Lambracht-Hall M, Konstantinidou AD, Theoharides TC. Regulation of mediator release from brain mast cells. Neuroscience, in press, 1989
Lichtenstein LM, Gilespie E. The effects of the H1 and H2 antihistamines on ‘allergic’ histamine and its inhibition by histamine. Journal of Pharmacology and Experimental Therapeutics 192: 441–450, 1975
Lin RV, Janniger CK, Schwartz RA, Lambert WC. Cold urticaria. American Family Physician 33: 145–150, 1986
Mansfield LE, Smith JA, Nelson HS. Greater inhibition of dermographia with combination of H1 and H2 antagonists. Annals of Allergy 50: 264–265, 1983
Marks R. Chronic idiopathic urticaria: the dilemma of treatment. International Journal of Dermatology 21: 19–20, 1982
Mathews KP. The urticarias: current concepts in pathogenesis and treatment. Drugs 30: 552–560, 1985
Mayumi H, Kimura S, Shimokawa T, Au-Young TF, Yayama T. Intravenous cimetidine as an effective treatment for systemic anaphylaxis and acute allergic skin reactions. Annals of Allergy 58: 447–450, 1987
Miller LG, Lee-Parritz A, Greenblatt DJ, Theoharides TC. High affinity benzodiazepine receptors on rat peritoneal mast cells and RBL-1 cells: binding characteristics and effects on granule secretion. Pharmacology 36: 52–60, 1988
Monroe EW. Treatment of urticaria. Dermatological Clinics 3: 51–55, 1985
Monroe EW, Cohen SH, Kalbfleisch J, Schulz CI. Combined H1 and H2 antihistamine therapy in chronic urticaria. Archives of Dermatology 117: 404–407, 1981
Naclerio RM, Meier HL, Adkinson NF, Kagey-Sobotka A, Meyers DA, et al. In vivo demonstration of inflammatory mediator release following nasal challenge with antigen. European Journal of Respiratory Diseases 64: 26–30, 1983
Neittaanmaki H, Myohanen T, Fraki JE. Comparison of cinnarizine, cyproheptadine, doxepin and hydroxyzine in treatment of idiopathic cold urticaria: usefulness of doxepin. Journal of the American Academy of Dermatology 11: 483–489, 1984
Neumann Y. Antihistamine therapy of chronic urticaria: results of a multicenter study with azatadine and terfenadine. Fortschritte der Medizin 102: 967–970, 1984
Newson B, Dahlstrom A, Enerback L, Ahlman H. Suggestive evidence for a direct innervation of mucosal mast cells. Neuroscience 10: 565–570, 1983
Noble EP, Bommer M, Liebisch D, Herz A. H1-histaminergic activation of catecholamine release by chromaffin cells. Biochemical Pharmacology 37: 221–228, 1988
Norman PS. Modulation of the mast cell and inhibition of its mediators: newer antihistaminic agents. Journal of Allergy and Clinical Immunology 76: 366–368, 1985
Ormerod AD, Baker R, Watt J, White MI. Terfenadine and brompheniramine maleate in urticaria and dermographism. Dermatologica 173: 5–8, 1986
Panula P, Yang H-YT, Costa E. Histamine-containing neurons in the rat hypothalamus. Proceedings of the National Academy of Sciences USA 81: 2572–2576, 1984
Paul E, Bodeker RH. Comparison of astemizole and terfenadine in the treatment of chronic urticaria: a randomized double-blind study of 40 patients. Zeitschrift für Hautkrankheiten 60: 50–55, 1985
Paul E, Bodeker RH. Treatment of chronic urticaria with terfenadine and ranitidine: a randomized double-blind study in 45 patients. European Journal of Clinical Pharmacology 31: 277–280, 1986
Paul E, Pfeffer M, Bodeker RH. Therapy of urticaria with H1 and H2 antihistamines: results of clinical and experimental studies. Zeitschrift für Hautkrankheiten 62: 401–402, 1987
Parkin JV, Ackroyd ED, Glickman S, Holsley M, Lorenze W. Release of histamine by H2-receptor antagonists. Lancet 2: 938–939, 1982
Payan DG, McGillis JP, Goetzl EJ. Neuroimmunology. Advances in Immunology 39: 299–323, 1986
Pinol J, Carapeto FJ. Ketotifen in the treatment of chronic urticaria and angioneurotic edema. Allergologia et Immunopathologia (Madrid) 12: 19–27, 1984
Ray JA. The development of a new antihistamine: astemizole. New England Regional Allergy Proceedings 6: 71–77, 1985
Read GW, Luganoff D. Inhibition of mast cell degranulation and histamine release by arylalkylamines. Federation Proceedings 36: 1023, 1977
Rebhun J. Hypothetical role of H2 blockers on chronic urticaria. Annals of Allergy 47: 440–442, 1981
Richards DM, Brogden RN, Heel RC, Speight TM, Avery GS. Oxatomide: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 27: 210–231, 1984a
Richards DM, Brogden RN, Heel RC, Speight TM, Avery GS. Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 28: 38–61, 1984b
Roberts LJ, Marney SR, Oates JA. Blockade of the flush associated with metastatic gastric carcinoid by combined histamine H1 and H2 receptor antagonists: evidence for an important role of H2 receptors in human vasculature. New England Journal of Medicine 300: 236–238, 1979
Rombaut N, Vanden-Bussche G. Total review of all results collected world wide with astemizole. Zeitschrift für Hautkrankheiten 60: 29–42, 1985
Rosch PJ. Stress and illness. Journal of the American Medical Association 242: 427–428, 1979
Rusli M. Cimetidine treatment of recalcitrant acute allergic urticaria. Annals of Emergency Medicine 15: 1363–1365, 1986
Sahasrabudhe DM, McCune CS, O’Donnell RW, Hershaw EC. Inhibition of suppressor T lymphocytes (Ts) by cimetidine. Journal of Immunology 138: 2760–2763, 1987
Salo OP, Kauppinen K, Mannisto PT. Cimetidine increases the plasma concentration of hydroxyzine. Acta Dermato-Venereologica 66: 349–350, 1986
Sauer RR, Steigleder GK. Effect of ketotifen and oxatomide on histamine liberation due to exposure in cold urticaria. Zeitschrift für Hautkrankheiten 58: 1768–1772, 1983
Schwartz J-C, Arrang J-M, Garbarg M, Korner M. Properties and roles of the three subclasses of histamine receptors in brain. Journal of Experimental Biology 124: 203–224, 1986
Serafin WE, Austen KF. Current concepts: mediators of immediate hypersensitivity reactions. New England Journal of Medicine 317: 30–34, 1987
Seropian E, Iamandescu IB, Filip V. Clinical and therapeutical aspects of cold urticaria (urticaria and frigore). Allergologia et Immunopathologia (Madrid) 12: 303–311, 1984
Shelley WB. Commentary: antihistamines and the treatment of urticaria. Archives of Dermatology 119: 442–444, 1983
Singh G. H2-blockers in chronic urticaria. International Journal of Dermatology 23: 627–628, 1984
Skofitsch G, Savitt JM, Jacobowitz DM. Suggestive evidence for a functional unit between mast cells and substance P fibers in the rat diaphragm and mesentery. Histochemistry 82: 5–8, 1985
Soloman GF, Amkraut AA. Psychoneuroendocrinological effects on the immune response. American Review of Microbiology 35: 155–184, 1981
Sorkin EM, Heel RC. Terfenadine. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 29: 34–56, 1985
Soter NA, Austen KF, Wasserman SI. Oral disodium cromoglycate in the treatment of systemic mastocytosis. New England Journal of Medicine 301: 465–469, 1979
Stein M, Keller SE, Schleifer SJ. Stress and immunomodulation: the role of depression and neuroendocrine function. Journal of Immunology 135: 826–833, 1985
Sullivan TJ. Pharmacologic modulation of whealing response to histamine in human skin: identification of doxepin as a potent inhibitor. Journal of Allergy and Clinical Immunology 69: 260–267, 1982
Sussman GL, Harvey RP, Schocket AL. Delayed pressure urticaria. Journal of Allergy and Clinical Immunology 70: 337–342, 1982
Theoharides TC. Mast cells and migraines Perspectives in Biology and Medicine 122: 995–996, 1986a
Theoharides TC. Allergy and antihistamines: a new riddle. Archives of Dermatology 122: 995–996, 1986b
Theoharides TC. Mast cells: the immune gate to the brain. Life Sciences, in press, 1989
Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW. Differential release of serotonin and histamine from mast cells. Nature 297: 229–231, 1982
Theoharides TC, Douglas WW. Somatostatin induces secretion from rat peritoneal mast cells. Endocrinology 102: 1637–1640, 1978
Theoharides TC, Kraeuter Kops S, Bondy PK, Askenase PW. Differential release of serotonin without comparable histamine under diverse conditions in the rat mast cell. Biochemical Pharmacology 34: 1389–1398, 1985
Theoharides TC, Sieghart W, Greengard P, Douglas WW. Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. Science 207: 80–82, 1980
Ting S, Rauls DO, Reiman BEF. Inhibitory effect of hydroxyzine on antigen-induced histamine release in vivo. Journal of Allergy and Clinical Immunology 75: 63–66, 1985
Togias AG, Naclerio RM, Warner J, Proud D, Kagey-Sootka A, et al. Demonstration of inhibition of mediator release from human mast cells by azatadine base: in vivo and in vitro evaluation. Journal of the American Medical Association 255: 225–229, 1986
Tokura Y, Takigawa M, Yamauchi T, Yamada M. Solar urticaria: a case with good therapeutic response to cimetidine. Dermatologica 173: 224–228, 1986
Trunch A, White JR, Pearce FL. Effect of ketotifen and oxatomide on histamine secretion from mast cells. Agents and Actions 12: 206–209, 1982
Tsakalos ND, Theoharides TC, Kraeuter-Kops S, Askenase PW. Induction of mast cell secretion by parathormone. Biochemical Pharmacology 32: 355–360, 1982
Twarog AP. Urticaria in childhood: pathogenesis and management. Pediatric Clinics of North America 30: 887–898, 1983
Vanden-Bussche G, Emanuel MB, Rombaut N. Clinical profile of astemizole: a survey of 50 double-blind trials. Annals of Allergy 58: 184–188, 1987
Vaughan WT. Practice of allergy, pp. 1002–1004, Mobsy, St Louis, 1939
Vliagoftis H, Kotkow K, Theoharides TC. Amitriptyline decreases intracellular calcium ion levels during inhibition of histamine secretion from mast cells. Biochemical Pharmacology, in press, 1989
Wiesner-Menzel L, Schulz B, Vakilzadeh F, Czarnetski PM. Electron microscopic evidence for a direct contact between nerve fibers and mast cells. Acta Desmatoneuer 61: 465–469, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Theoharides, T.C. Histamine2 (H2)-Receptor Antagonists in the Treatment of Urticaria. Drugs 37, 345–355 (1989). https://doi.org/10.2165/00003495-198937030-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198937030-00004